Intranasal Delivery of HPV Therapeutic Vaccines for Enhanced Mucosal Immunization and Anti-Tumor Immunity
Persistent infection with high-risk human papillomavirus (HPV) is widely acknowledged as the leading cause of cervical, oral, and other malignant cancers. Currently approved HPV vaccines are prophylactic and show no significant therapeutic effect on pre-existing infections or lesions. Considering the important role of mucosal vaccines in inducing localized immune responses against mucosal cancer, in this work, we developed salcaprozate-modified chitosan (SCS) for intranasal delivery of the HPV vaccine. We found that SCS can self-assemble with the E7